Biovaxys Technology Corp
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S)… Read more
Biovaxys Technology Corp (BVAXF) - Net Assets
Latest net assets as of April 2025: $-2.73 Million USD
Based on the latest financial reports, Biovaxys Technology Corp (BVAXF) has net assets worth $-2.73 Million USD as of April 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.10 Million) and total liabilities ($3.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.73 Million |
| % of Total Assets | -248.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -120.09% |
| 10-Year Change | N/A |
| Growth Volatility | 2352.61 |
Biovaxys Technology Corp - Net Assets Trend (2018–2024)
This chart illustrates how Biovaxys Technology Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biovaxys Technology Corp (2018–2024)
The table below shows the annual net assets of Biovaxys Technology Corp from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-10-31 | $-1.92 Million | +43.06% |
| 2023-10-31 | $-3.37 Million | -335.93% |
| 2022-10-31 | $-773.53K | -109.46% |
| 2021-10-31 | $8.18 Million | -14.46% |
| 2020-10-31 | $9.56 Million | +4928.01% |
| 2019-10-31 | $190.11K | +350.42% |
| 2018-10-31 | $-75.92K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biovaxys Technology Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3108915800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $29.33 Million | % |
| Total Equity | $-1.92 Million | 100.00% |
Biovaxys Technology Corp Competitors by Market Cap
The table below lists competitors of Biovaxys Technology Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RangDong Plastic JSC
VN:RDP
|
$1.01 Million |
|
Wirecard AG
PINK:WRCDF
|
$1.01 Million |
|
Identa Corp
OTCQB:IDTA
|
$1.01 Million |
|
XSLR
F:XSLR
|
$1.01 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
$1.01 Million |
|
Agro Capital Management Corp
PINK:ACMB
|
$1.01 Million |
|
Maple Peak Investments Inc
V:MAP
|
$1.01 Million |
|
MNB Holdings Corp
OTCQB:MNBO
|
$1.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biovaxys Technology Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,372,061 to -1,920,122, a change of 1,451,939.
- Net loss of 3,954,781 reduced equity.
- New share issuances of 3,160,512 increased equity.
- Other factors increased equity by 2,246,208.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.95 Million | -205.97% |
| Share Issuances | $3.16 Million | +164.6% |
| Other Changes | $2.25 Million | +116.98% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biovaxys Technology Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-10-31 | $0.00 | $0.04 | x |
| 2019-10-31 | $0.01 | $0.04 | x |
| 2020-10-31 | $0.17 | $0.04 | x |
| 2021-10-31 | $0.10 | $0.04 | x |
| 2022-10-31 | $-0.01 | $0.04 | x |
| 2023-10-31 | $-0.23 | $0.04 | x |
| 2024-10-31 | $-0.07 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biovaxys Technology Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-35.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -121.04% | 0.00% | 0.00x | 1.61x | $-249.13K |
| 2020 | -12.29% | 0.00% | 0.00x | 1.09x | $-2.13 Million |
| 2021 | -78.98% | 0.00% | 0.00x | 1.04x | $-7.28 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.65 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.35 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.76 Million |
Industry Comparison
This section compares Biovaxys Technology Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biovaxys Technology Corp (BVAXF) | $-2.73 Million | -121.04% | N/A | $1.01 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |